進行固形腫瘍患者におけるINCB123667の研究

基本情報

NCT ID

NCT05238922

ステータス

募集中

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

604

治験依頼者名

Incyte Corporation

概要

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)